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Abstract
Background: Urokinase-type plasminogen activator (uPA) plays a major role in extracellular
proteolytic events associated with tumor cell growth, migration and angiogenesis. Consequently,
uPA is an attractive target for the development of small molecule active site inhibitors. Most of the
recent drug development programs aimed at nonpeptidic inhibitors targeted at uPA have focused
on arginino mimetics containing amidine or guanidine functional groups attached to aromatic or
heterocyclic scaffolds. There is a general problem of limited bioavailability of these charged
inhibitors. In the present study, uPA inhibitors were designed on an isocoumarin scaffold containing
uncharged substituents.
Results: 4-Chloro-3-alkoxyisocoumarins were synthesized in which the 3-alkoxy group contained
a terminal bromine; these were compared with similar inhibitors that contained a charged terminal
functional group. Additional variations included functional groups attached to the seven position of
the isocoumarin scaffold. N- [3-(3-Bromopropoxy)-4-chloro-1-oxo-1H-isochromen-7-
yl]benzamide was identified as an uncharged lead inhibitor of uPA, Ki = 0.034 µM. Molecular
modeling of human uPA with these uncharged inhibitors suggests that the bromine occupies the
same position as positively charged arginino mimetic groups.
Conclusion: This study demonstrates that potent uncharged inhibitors of uPA can be developed
based upon the isocoumarin scaffold. A tethered bromine in the three position and an aromatic
group in the seven position are important contributors to binding. Although the aim was to develop
compounds that act as mechanism-based inactivators, these inhibitors are competitive reversible
inhibitors.
Background
Multiple proteases, including matrix metalloproteases
(MMP-2, MMP-9 and MMP-14), cysteine proteases
(cathepsin B and cathepsin L), aspartyl protease (cathep-
sin D) and serine proteases (plasmin, matriptase and
urokinase) participate in cancer cell growth, metastasis
and angiogenesis [1-4]. High expression of proteases
often correlates with a poor prognosis [5,6]. Urokinase
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(uPA) plays an especially important role in extracellular
proteolysis that contributes to cancer cell metastasis.
Many cancer cells secrete pro-uPA and its receptor uPAR;
binding of pro-uPA to uPAR leads to its activation, with
subsequent generation of plasmin by the uPA-catalyzed
hydrolysis of extracellular plasminogen [7,8]. The
increased production of plasmin leads to degradation of
extracellular matrix both by plasmin itself and by other
proteases that are activated by plasmin. The surface loca-
tion of bound uPA provides directionality to the degrada-
tion of matrix, thereby assisting the directional migration
of cancer cells. uPA in complex with uPAR also affects
other biological processes including signaling pathways
that influence cell proliferation [9]. uPA has become a
major target for development of non-peptidic small mol-
ecule inhibitors as potential anti-cancer drugs [10,11].
Most of the efforts to develop potent and selective inhibi-
tors of uPA have focused on arginino mimetics based
upon the trypsin-like specificity of uPA. The development
of selective inhibitors of uPA is a challenge due to the
large number of serine proteases with trypsin-like specifi-
city, including factor VII, factor X and tissue-type plas-
minogen activator. Extensive structure-based drug
development has provided potent and selective inhibitors
of uPA; these generally are arginino mimetics with ami-
dine or guanidine functional groups built onto aromatic
or heterocyclic scaffolds (Figure 4) [12-16]. A major limi-
tation to the use of these inhibitors is their poor bioavail-
ability, which is at least partly owing to the presence of the
positively charged amidine or guanidine group. This has
limited clinical studies of these uPA inhibitors.
In the present study, we have focused on the synthesis and
testing of uncharged compounds as leads for the develop-
ment of uPA inhibitors with improved bioavailability. 4-
Chloroisocoumarin was selected as the scaffold, in which
substituted 3-alkoxy groups were introduced that con-
tained neutral terminal functional groups or charged ter-
minal functional groups [17]. Additional substituents
were introduced into the seven position. 4-Chloroisocou-
marin scaffolds have been used in studies of serine pro-
tease inhibitors, [17] but with limited application to uPA
[18]. The choice of the 4-chloroisocoumarin scaffold was
based upon the potential of these compounds to function
as mechanism-based inactivators [17]. In this study we
demonstrate that introduction of bromine in place of a
terminal charged functional group in the 3-alkoxy substit-
uent provides uncharged uPA inhibitors with low micro-
molar dissociation constants. Further introduction of
substituents at the seven position of these uncharged uPA
inhibitors provides compounds with low nanomolar dis-
sociation constants. These inhibitors may serve as lead
compounds for the development of new uPA inhibitors.
Molecular modeling with human uPA suggests that the
bromine occupies the same site as the arginino mimetic
functional groups.
Results and discussion
Chemistry
Compounds 4a-4e, which are 3-bromoalkoxy-4-chloroi-
socoumarins, were synthesized as shown in Figure 1. Two
of the compounds, 4a and 4b, have a nitro group in posi-
tion seven. These compounds have varying lengths of bro-
moalkoxy groups tethered in position three of the
isocoumarin scaffold. 5-Nitrohomophthalic acid (1a) was
prepared by regioselective nitration of homophthalic acid
(1c) using fuming nitric acid [19]. 5-Nitrohomophthalic
acid (1a) and homophthalic acid (1c) were monoesteri-
fied using bromoalcohols, compounds 2c-2e, in the pres-
ence of sulfuric acid to give moderate yields of
bromoesters, 3a-3e. Monoesterification at the saturated
acid has been attributed to the mesomeric effect of the car-
boxyl with the double bond in the aryl ring [20]. Cycliza-
tion of the esters, compounds 3a-3e, with phosphorus
pentachloride in toluene gave 3-bromoalkoxy-4-chloroi-
socoumarins, 4a-4e, in moderate yields using a variation
of a published method [17]. Compounds 4a-4e were syn-
thesized to test the importance of an uncharged group in
the three position of 4-chloroisocoumarins and the length
of the tether of the alkoxy group.
Compounds  5c-5e  are 3-isothioureidoalkoxy-4-chloroi-
socoumarin salts and were synthesized as shown in Figure
1. Nucleophilic substitution of the bromine in com-
pounds 4c-4e was achieved by refluxing these compounds
with thiourea in tetrahydrofuran to give the hydrobro-
mide salts, compounds 5c-5e, in moderate yields. The 7-
nitrosubstituted isocoumarins, compounds 4a  and  4b,
did not give any identifiable products when reacted with
thiourea in tetrahydrofuran. Compounds 5c-5e were syn-
thesized to test the importance of a charged alkoxy group
in the three position of 4-chloroisocoumarins.
The synthesis of 3-bromo-4-chloro-7-aminoisocou-
marins, compounds 6a  and  6b, is shown in Figure 2.
These 7-aminoisocoumarins were prepared by reduction
of 3-bromoalkoxy-4-chloro-7-nitroisocoumarins, com-
pounds 4a and 4b, using hydrogen in the presence of a
catalytic amount of 10% palladium on charcoal under
pressure in methanol. Compounds 6a and 6b were syn-
thesized to test the importance of an amino group in the
seven position and an uncharged alkoxy group in the
three position of 4-chloroisocoumarins. Nucleophilic
substitution of the bromine in compounds 6a and 6b by
reaction with thiourea afforded hydrobromide salts, 7a
and 7b. Compounds 7a and 7b were synthesized to test
the importance of a charged alkoxy group in the three
position of 4-chloro-7-aminoisocoumarins.BMC Chemical Biology 2006, 6:1 http://www.biomedcentral.com/1472-6769/6/1
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3-Bromoalkoxy-4-chloro-7-benzamidoisocoumarins,
compounds 8a and 8b, were synthesized by reaction of 6a
and 6b with benzoyl chloride in the presence of triethyl-
amine (Figure 2). Compounds 8a and 8b were synthe-
sized to test the importance of an uncharged alkoxy group
in the three position and a hydrophobic benzamide group
in the seven position of 4-chloroisocoumarins. The two
amides, 8a and 8b were reacted with thiourea to give the
hydrobromide salts, 9a and 9b, in moderate yields. Com-
pounds 9a and 9b were synthesized to test the importance
of a charged alkoxy group in the three position and a
hydrophobic benzamide group in the seven position of 4-
chloroisocoumarins.
Figure 3 describes the synthesis of two 7-nitro-3-alkox-
yisocoumarins, compounds 10a and 10b, which do not
have a chlorine atom at position four. The synthesis of
compound 10c, which is a 3-alkoxy-4-trifluoroacetyliso-
Scheme 1 Figure 1
Scheme 1
Scheme 2 Figure 2
Scheme 2BMC Chemical Biology 2006, 6:1 http://www.biomedcentral.com/1472-6769/6/1
Page 4 of 11
(page number not for citation purposes)
coumarin, is also described in Figure 3. Cyclization of
compounds 3a and 3b, which have a nitro group in posi-
tion seven, using trifluoroacetic anhydride gave com-
pounds  10a  and  10b, which contain a hydrogen at
position four. On the other hand, cyclization of 3c which
does not contain a nitro group in position seven gave
compound 10c, which contains a trifluoroacetyl group in
position four. This may be attributed to the fact that the
intramolecular cyclization of the initially formed enol is
faster when there is resonance stabilization by the electron
withdrawing nitro group. When the nitro group is absent
the initially formed enol reacts with trifluoroacetic anhy-
dride giving compound 10c. Compounds 10a and 10b
were synthesized to test the importance of a chlorine atom
in position four and the presence of an electron withdraw-
ing group in position seven of the isocoumarins. Com-
pound  10c  gives information on the importance of a
trifluoroacetyl group in position four of the isocoumarins.
Compound 11, a 7-amino-3-alkoxyisocoumarin, was pre-
pared by reduction of compound 10a using hydrogen in
the presence of a catalytic amount of 10% palladium on
charcoal under pressure in methanol (Figure 3). Com-
pound 11  was synthesized to test the importance of a
chlorine atom in position four and the presence of an
Scaffolds that have been utilized to develop arginino mimetic uPA inhibitors in the amidine (I-VI) and guanidine (VII-IX) series  [12–16] Figure 4
Scaffolds that have been utilized to develop arginino mimetic uPA inhibitors in the amidine (I-VI) and guanidine (VII-IX) series 
[12–16].
Scheme 3 Figure 3
Scheme 3BMC Chemical Biology 2006, 6:1 http://www.biomedcentral.com/1472-6769/6/1
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electron donating group in position seven of the isocou-
marins.
Structure activity relationships
On the basis of docking studies using the crystal structure
of human uPA [15] we examined whether the 4-chloroi-
socoumarin scaffold containing 3-alkoxy substituents is
predicted to be a good template for the design of uPA
inhibitors. Our interest focused on compounds having an
uncharged bromine group in place of the charged
arginino mimetic group at the terminal position of the 3-
alkoxy group. Specifically, we compared the experimen-
tally determined dissociation constants with the docking
orientations predicted for compounds with the isocou-
marin scaffold containing a charged isothiourea group or
an uncharged bromine atom in the terminal 3-alkoxy
position.
The first series of compounds compared the 4-chloroiso-
coumarin scaffold with 3-alkoxy substituents where the
terminal functional group was an isothiourea group or
bromine atom. The distance between the terminal group
and the alkoxy oxygen was varied by the insertion of
methylene units (Table 1). The designed inhibitors were
shown to dock in the area of the active site containing the
catalytic triad (serine 195, histidine 57, aspartic acid 102)
and aspartic acid 189, which is the residue in trypsin-like
enzymes that forms a salt bridge with the arginino
mimetic groups. All of the compounds were predicted to
reside in the active site with the thiourea group and the
bromine atom in the S1-subsite which contains aspartic
acid 189. Compounds 4c-4e, which are 3-bromoalkoxy-4-
chloroisocoumarins, are oriented in the active site with
the uncharged bromine atom within 2.81–3.12 Å of
aspartic acid 189. The best inhibitor in this series, com-
pound 4d, exhibited Ki = 9 µM. Modeling of inhibitor 4d
with uPA also showed that three methylene units between
the bromine and oxygen of the 3-alkoxy substituent pro-
vided the closest interaction between the isocoumarin car-
bonyl and the active site residue serine 195. Nevertheless,
compound  4d  provided simple competitive inhibition
with no evidence of rapid inactivation of uPA by 4d. For
comparison, compounds 5c-5e  were included in this
series. These compounds contain the charged isothiourea
group in place of the bromine atom and two, three or four
methylene units between the isothiourea group and the
oxygen atom. Modeling suggests that compounds 5c-5e
are all oriented in the active site with the charged isothiou-
rea group forming a salt bridge with aspartic acid 189. The
predicted distance between the isothiourea group and
aspartic acid 189 for compounds 5c-5e ranges from 2.49
– 2.58 Å. The best inhibitor, compound 5c, exhibited a Ki
= 0.033 µM. Modeling suggested that the 3-alkoxy substit-
uent with two methylenes between the isothiourea group
and oxygen atom provided the closest interactions
between the isocoumarin carbonyl and the active site ser-
ine. Clearly, the charged isothiourea group provides 3.5–
4 kcal/mol more binding energy than the bromine atom
in its interactions with aspartic 189 and surrounding resi-
dues. Thus, there is a large penalty in moving to the
uncharged bromoalkoxy inhibitors. This may be the pen-
alty that must be accepted if uncharged uPA inhibitors
with improved bioavailability are to be developed in place
of the charged uPA inhibitors that have been described
[12-16].
The second series of uPA inhibitors examined the effects
of substituents in the seven position. Compounds 6a, 6b,
7a and 7b, which are 7-amino-4-chloroisocoumarins are
attractive candidates because of the increased hydrogen
bonding possibilities. Based upon modeling, compounds
6a and 6b, which have an uncharged bromine atom on
the 3-alkoxy group, are within 2.80-3.15 Å of aspartic acid
189. Compounds 7a and 7b, which have a charged iso-
thiourea group within 2.75–2.85 Å from aspartic acid
189. Compounds 8a, 8b, 9a and 9b are 7-substituted ben-
zamides that were synthesized to investigate potential
hydrophobic interactions from groups at the seven posi-
tion. The uncharged bromine atoms of compounds 8a
and 8b are within 2.93–3.32 Å of aspartic acid 189. The
charged isothiourea group in compounds 9a and 9b are
within 2.75 Å of aspartic acid 189. In the isothiourea
series (7a, 7b, 9a and 9b), the 7-substituted compounds
did not exhibit any significant improvement in binding to
uPA (Table 1). By comparison, the compounds in the
bromo series with hydrophobic groups at the seven posi-
tion (8a and 8b) exhibited markedly improved binding;
for  8b, Ki = 0.034 µM, which represents a 300-fold
improvement over 4d. Inhibitor 8b was the best inhibitor
in the bromo series and can be viewed as a promising lead
compound for development of uncharged inhibitors of
uPA. The improvement that the benzamide group in 8a
and 8b of the bromo series provided compared to the lack
of improvement that the benzamide group provided in
the isothiourea series may relate to increased flexibility.
The bromo group has weak interactions with aspartic acid
189; this may allow the inhibitors in the bromo series to
slide within the active site and S1 sub-site to orientations
that allow the 7-benzamide group to find additional ener-
getically favorable interactions. By comparison, the strong
salt bridge in the uPA complexes with inhibitors in the
isothiourea series may lock the inhibitors into the S1 sub-
site. The modeled uPA complexes with inhibitors 8b and
9b are shown in Figures 5 and 6 respectively. The addi-
tional binding energy for 8b appears to be the result of
additional interactions of the aromatic ring of the benza-
mide group, especially with disulfide cysteine 58-cysteine
42.BMC Chemical Biology 2006, 6:1 http://www.biomedcentral.com/1472-6769/6/1
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The presence of a 7-nitro group also was beneficial. Com-
pounds 4a and 4b, which are 3-bromoalkoxy-7-nitroiso-
coumarins, showed improved binding to uPA compared
to the unsubstituted compounds. Compound 4b which
has three methylene units between the bromine atom and
the oxygen of the 3-alkoxy group has a Ki = 2.4 µM, which
is an 4-fold improvement over the unsubstituted com-
pound 4d.
Compounds 10a, 10b and 11 were synthesized to deter-
mine whether the chlorine atom in position four contrib-
uted to binding. 3-Bromoalkoxy-7-substituted
isocoumarins without a chlorine atom in the four posi-
tion show dissociation constants that are about 2 fold
higher compared to their counterparts that have a chlo-
rine atom in the four position suggesting a modest role for
the chlorine atom (Table 1). Compound 10c which has
trifluoroacetyl group in the four position did not show
improved binding.
The isocoumarin-based inhibitors (Table 1) have the
potential to function as suicide inhibitors or as substrates.
However, simple reversible competitive inhibition was
observed. The inhibitors were stable for several hours at
neutral pH, as evidenced by no change in the spectral
properties of the inhibitors. Addition of uPA for several
hours at concentrations ten-fold higher than used in the
kinetic studies did not produce any detectable changes in
the inhibitors, suggesting that the inhibitors are not weak
substrates of uPA. In addition, there was no loss of
enzyme activity under these conditions, suggesting that
the inhibitors are not functioning as suicide inhibitors.
The observation of simple competitive inhibition is con-
sistent with the modeling results in which the predicted
orientations of the isocoumarin scaffold bound in the
active site of uPA (figures 5 and 6) are not favorable for
attack by serine 195.
Conclusion
Inhibition of uPA by uncharged inhibitor 8b represents a
proof of concept that uPA inhibitors without a charged
arginino mimetic group can be developed. Inhibitor 8b,
which exhibits a dissociation constant in the low
nanomolar range comparable to those of known arginino
mimetic inhibitors, represents a lead compound for future
development of uncharged inhibitors of uPA. The present
study did not address the issue of specificity. Many previ-
ous studies of uPA inhibitors with arginino mimetic
groups attached to various scaffold have resulted in the
development of selective inhibitors of uPA. This informa-
tion should be useful for developing selective uncharged
inhibitors of uPA.
Methods
Modeling
The x-ray crystal structure of human urokinase (pdb code
1EJN) was obtained from the protein data bank. All com-
pounds shown in Table 1 were docked to the enzyme
using Autodock 3.0 [21,22] on a cluster of Silicon Graph-
ics workstations consisting of Octanes and O2s. The com-
pounds were prepared using Sybyl 7.0 (Tripos Inc., St.
Louis, MO). The molecules were drawn in, assigned par-
tial charges using the included Gasteiger-Hückel method
and energy minimized using the BFGS method. Minimi-
zations were run for 10,000 iterations and the rotatable
bonds defined before docking. The protein was prepared
before docking in Sybyl by removing non-native sub-
strates and water molecules. Polar hydrogens and Koll-
man Uni charges were added to the protein as well. The
Molecular model of human uPA complexed with inhibitor 9b Figure 6
Molecular model of human uPA complexed with inhibitor 9b. 
The isothiourea is within 2.02 Å of aspartic acid 189.
Molecular model of human uPA complexed with inhibitor 8b Figure 5
Molecular model of human uPA complexed with inhibitor 8b. 
The bromine is within 3.32 Å of aspartic acid 189.BMC Chemical Biology 2006, 6:1 http://www.biomedcentral.com/1472-6769/6/1
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Table 1: Dissociation constants for inhibition of human uPA
Structure Number Ki (µM) Structure Number Ki (µM)
4a 1.8 ± 0.2 7a 0.020 ± 0.003
4b 2.4 ± 0.2 7b 0.038 ± 0.005
4c 14 ± 1 8a 1.4 ± 0.2
4d 9 ± 1 8b 0.034 ± 0.002
4e 18 ± 2 9a 0.084 ± 0.007
5c 0.033 ± 0.004 9b 0.010 ± 0.008
5d 0.055 ± 0.003 10a 4.2 ± 0.4
5e 0.14 ± 0.02 10b 4.3 ± 0.3
6a 12 ± 1 10c 14 ± 2
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molecules were docked in an area defined around the
active site serine 195 by a cube of 60 × 60 × 60 Å.
Chemical synthesis
Reagent quality solvents were used without purification.
Benzoyl chloride was distilled before use. Melting points
were determined on a Thomas Hoover capillary melting
point apparatus and are uncorrected. NMR spectra were
recorded on a Bruker AC250 NMR spectrometer in CDCl3
unless noted. Chemical shifts are in ppm (δ) relative to
TMS. High resolution mass spectra were recorded on a
Waters/Micromass LCT- premier. Analytical data was
obtained from Galbraith laboratories, Knoxville TN. 5-
Nitrohomophthalic acid was prepared as reported [19].
Compounds 3a-3e, 4a-4e, 5c-5e, 6a, 6b, 8a, 8b 10a, 10b
and 11 were prepared according to published procedures
[23]. Compounds 7a,  7b,  9a,  9b  were prepared as
reported [24].
Kinetics
Human urokinase (Sigma/Aldrich, St. Louis, MO) and
Spectrozyme UK (American Diagnostica, Stamford, CT)
were used for the kinetic studies. Enzyme activity was rou-
tinely measured in 1 ml volumes of 0.1 M Tris, pH 8.8,
Spectrozyme UK (10 µM to 150 µM) and 0.64 µg (3,770
units/mg protein) human urokinase. Reactions were
monitored at 405 nm, 25°C, with a Perkin/Elmer Lambda
S2 UV/vis spectrophotometer. Michaelis constants and Ki
values were determined from initial rate data, measured at
8 to 10 substrate concentrations, by non-linear regression
analysis with SigmaPlot's Enzyme Kinetics Module™ (Chi-
cago, IL, USA).
Experimental
2- [2-(2-Bromoethoxy)-2-oxoethyl]-5-nitrobenzoic acid
(3a) (66% yield) Tan crystals: mp 113–115°C (lit. [25]
90°C);1H NMR: δ 3.50 (t, 2H, J = 5.96 Hz) 4.21 (s, 2H)
4.43 (t, 2H, J = 6.06 Hz) 7.51 (d, 1H, J = 8.34 Hz) 8.39
(dd, 1H, J = 2.59 Hz, 8.39 Hz) 8.98 (d, J = 2.39 Hz);13C
NMR:  δ 28.40, 40.13, 64.17, 126.24, 126.45, 130.97,
133.32, 142.59, 146.84, 167.46, 169.63.
2- [2-(3-Bromopropoxy)-2-oxoethyl]-5-nitrobenzoic
acid (3b) (51% yield) White crystals: mp 122–123°C; 1H
NMR: δ 2.19 (m, 2H) 3.44 (t, 2H, J = 6.56 Hz) 4.18 (s, 2H)
4.28 (t, 2H, J = 5.96 Hz) 7.51 (d, 1H, J = 8.34 Hz) 8.39
(dd, 1H, J = 2.39 Hz, 8.35 Hz) 8.98 (d, 1H, J = 2.18 Hz)
9.78 (br s, 1H); 13C NMR: δ 29.18, 31.58, 40.51, 63.12,
126.84, 127.52, 129.77, 143.37, 147.47, 169.92, 170.05.
2- [2-(2-Bromoethoxy)-2-oxoethyl]benzoic acid (3c)
(50% yield) Tan crystals: mp 82–83°C; 1H NMR: δ 3.50 (t,
2H, J = 6.25 Hz) 4.07 (s, 2H) 4.40 (t, 2H, J = 6.25 Hz) 7.27
(d, 1H, J = 7.75 Hz) 7.45 (t, 1H, J = 7.55 Hz) 7.54 (td, 1H,
J = 1.39 Hz, 7.55 Hz) 8.14 (d, 1H, J = 7.74 Hz); 13C NMR:
δ 28.50, 40.68, 64.08, 127.65, 128.32, 131.95, 132.43,
133.35, 136.40, 170.86, 172.43.
2- [2-(3-Bromopropoxy)-2-oxoethyl]benzoic acid (3d)
(70% yield) White crystals: mp 79–80°C; 1H NMR: δ 2.16
(m, 2H, J = 6.31 Hz) 3.42 (t, 2H, J = 6.55 Hz) 4.05 (s, 2H)
4.24 (t, 2H, J = 5.96 Hz) 7.27 (d, 1H, J = 7.55 Hz) 7.40 (t,
1H, J = 7.65 Hz) 7.54 (td, 1H, J = 1.2, 7.35 Hz) 8.14 (dd,
1H, J = 0.99, 7.74 Hz); 13C NMR: δ 29.50, 31.80, 40.80,
62.52, 127.60, 128.35, 131.91, 132.41, 133.35, 136.86,
171.17, 172.47.
2- [2-(4-Bromobutoxy)-2-oxoethyl]benzoic acid (3e) A
solution of 4-bromo-1-butanol (2e, 6.0 mL, 41.6 mmol),
homophthalic acid (1c, 2.5 g, 13.8 mmol), and five drops
of concentrated sulfuric acid was refluxed in benzene (50
mL) for four hours. The solution was cooled and washed
with water (2 × 25 mL), brine (1 × 25 mL), and dried over
magnesium sulfate. Filtration and evaporation of the sol-
vent gave a dark oil that was triturated with hexane to
afford a crude solid. Recrystallization from hexane/ethyl
acetate gave 0.91 g (40%) of compound 3e as white crys-
tals: mp 84–86°C; 1H NMR: δ 1.79 (m, 2H) 1.87 (m, 2H)
3.38 (t, 2H, J = 6.45 Hz) 4.04 (s, 2H) 4.13 (t, 2H, J = 6.15
Hz) 7.27 (d, 1H, J = 7.55 Hz) 7.39 (t, 2H, J = 7.65 Hz)
7.54 (td, 1H, J = 1.4, 7.55 Hz) 8.13 (dd, 1H, J = 1.19, 7.74
Hz);  13C NMR: δ 27.33, 29.32, 33.19, 63.85, 127.56,
128.41, 131.88, 132.42, 133.33, 136.77, 171.32, 172.58.
3-(2-Bromoethoxy)-4-chloro-7-nitro-1H-isochromen-1-
one (4a) (43% yield) Yellow crystals: mp 126–128°C (lit.
[25] 120°C); 1H NMR: δ 3.67 (t, 2H, J = 6.16 Hz) 4.74 (t,
2H, J = 6.06 Hz) 7.86 (d, 1H, J = 8.94 Hz) 8.53 (dd, 1H, J
= 2.39 Hz, 8.94 Hz) 9.03 (d, 1H, J = 2.38 Hz); 13C NMR:
δ 27.72, 69.63, 90.86, 117.17, 123.81, 126.32, 129.82,
142.71, 145.47, 154.77, 157.06.
3-(3-Bromopropoxy)-4-chloro-7-nitro-1H-isochromen-
1-one (4b) (76% yield) Pale yellow crystals: mp 131–
6b 9.5 ± 1 11 65 ± 9
Table 1: Dissociation constants for inhibition of human uPA (Continued)
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134°C; 1H NMR: δ 2.37 (m, 2H) 3.59 (t, 2H, J = 6.26 Hz)
4.61 (t, 2H, J = 5.86 Hz) 7.81 (d, 1H, J = 8.94 Hz) 8.50
(dd, 1H, J = 2.09 Hz, 8.84 Hz) 8.99 (d, 1H, J = 1.79 Hz);
13C NMR: δ 28.49, 31.92, 68.56, 90.46, 116.93, 123.52,
126.22, 129.68, 142.77, 145.77, 155.34, 157.18.
3-(2-Bromoethoxy)-4-chloro-1H-isochromen-1-one
(4c) (30% yield) Yellow solid: mp 81–82°C; 1H NMR: δ
3.65 (t, 2H, J = 6.35 Hz) 4.64 (t, 2H, J = 6.35 Hz) 7.41 (t,
1H, J = 7.15 Hz) 7.74 (m, 2H) 8.20 (d, 1H, J = 7.75 Hz);
13C NMR: δ 28.07, 69.37, 92.09, 117.53, 122.47, 126.55,
130.06, 135.62, 137.35, 152.08, 159.01.
3-(3-Bromopropoxy)-4-chloro-1H-isochromen-1-one
(4d) (53% yield) Yellow crystals: mp 95–97°C; 1H NMR:
δ 2.33 (m, 2H) 3.60 (t, 2H, J = 6.35 Hz) 4.51 (t, 2H, J =
5.76 Hz) 7.40 (t, 1H, J = 6.75 Hz) 7.72 (m, 2H) 8.19 (d,
1H, J = 7.94 Hz); 13C NMR: δ 28.88, 32.26, 68.28, 91.91,
117.58, 122.39, 126.43, 130.12, 135.62, 137.57, 152.74,
159.33.
3-(4-Bromobutoxy)-4-chloro-1H-isochromen-1-one
(4e) A solution of 3e (0.75 g, 2.3 mmol) and phosphorus
pentachloride (1.23 g, 5.9 mmol) was refluxed in benzene
(50 mL) for fourteen hours. The orange solution was
cooled, washed with water (2 × 25 mL), saturated sodium
bicarbonate (2 × 15 mL), brine (1 × 25 mL), and dried
over magnesium sulfate. Filtration and evaporation of the
solvent gave a yellow oil. Trituration with hexane gave
0.55 g (70%) of compound 4e as white crystals: mp 75–
77°C; 1H NMR: δ 1.98 (m, 2H) 2.06 (m, 2H) 3.48 (t, 2H,
J = 6.25 Hz) 4.40 (t, 2H, J = 5.96 Hz) 7.38 (td, 1H, J = 1.59
Hz, 7.50 Hz) 7.70 (m, 2H) 8.17 (d, 1H, J = 7.55 Hz); 13C
NMR:  δ 27.33, 29.32, 33.12, 40.80, 63.81, 127.55,
128.41. 131.86, 132.38, 133.30, 136.76, 171.26, 172.29.
Exact mass calcd for C13H12BrClO3: 329.9658, observed
(M+H) 330.9734.
2- [2-(4-Chloro-1-oxo-1H-isochromen-3-
yloxy)ethyl]isothiourea hydrobromide (5c) (64% yield)
Yellow solid: mp 168–170°C (lit. [24] 167–169°C); 1H
NMR: (DMSO-d6) δ 3.65 (t, 2H, J = 5.66 Hz) 4.58 (t, 2H,
J = 5.67 Hz) 7.53 (t, 1H, J = 7.65 Hz) 7.69 (d, 1H, J = 8.14
Hz) 7.92 (t, 1H, J = 7.05 Hz) 8.13 (d, 1H, J = 7.75 Hz)
9.15 (br s, 4H); 13C NMR: δ 29.73, 68.11, 90.48, 117.18,
121.72, 126.70, 129.48, 135.99, 136.56, 152.18, 158.35,
169.11.
2- [3-(4-Chloro-1-oxo-1H-isochromen-3-yloxy)pro-
pyl]isothiourea hydrobromide (5d) (40% yield) Yellow
solid: mp 159–163°C (lit. [24] 165–167°C);1H NMR:
(DMSO-d6) 2.21 (m, 2H) 3.40 (t, 2H, J = 7.18 Hz) 4.55 (t,
2H, J = 6.11 Hz) 7.62 (td, 1H, J = 0.95, 7.60 Hz) 7.79 (d,
1H, J = 7.70 Hz) 8.02 (td, 1H, J = 1.23, 7.70 Hz) 8.23 (dd,
1H, J = 1.25, 7.50 Hz) 10.09 (br s, 4H); 13C NMR: δ 26.66,
28.53, 68.68, 90.43, 117.13, 121.66, 126.59, 129.47,
135.96, 136.66, 152.63, 158.53, 169.36.
2- [4-(4-Chloro-1-oxo-1H-isochromen-3-
yloxy)butyl]isothiourea hydrobromide (5e) A solution
of 4e (0.25 g, 0.75 mmol) and thiourea (0.075 g, 0.98
mmol) in dry tetrahydrofuran (25 mL) was refluxed for
forty-eight hours. The resulting pale yellow solid was fil-
tered and washed with hot tetrahydrofuran (3 × 10 mL) to
give 0.2 g (65%) of compound 5h as a pale yellow solid:
mp 160–162°C; 1H NMR: (DMSO-d6) δ 1.82 (br s, 4H)
3.24 (t, 2H, J = 6.45 Hz) 4.39 (t, 2H, J = 5.75 Hz) 7.50 (t,
1H, J = 7.45 Hz) 7.65 (d, 1H, 7.45 Hz) 7.89 (t, 1H, J = 7.25
Hz) 8.09 (d, 1H, J = 7.75 Hz) 9.07 (br s, 4H); 13C NMR: δ
24.92, 27.35, 29.59, 69.96, 90.20, 116.95, 121.56,
126.48, 129.45, 135.94, 136.73, 152.80, 158.59, 169.56.
7-Amino-3-(2-bromoethoxy)-4-chloro-1H-isochromen-
1-one (6a) Compound 4a (2.2 g, 6.3 mmol) was reduced
on a Parr apparatus with hydrogen over 10% palladium
on charcoal (50 mg) in ethanol (25 mL) until the reaction
stopped absorbing hydrogen. The solution was filtered
through celite and the filtrate was evaporated. The result-
ing crude solid was chromatographed (dichloromethane)
to give 1.55 g (78%) of compound 6a as yellow crystals:
mp 134–136°C, (lit. [26] 134–137°C); 1H NMR: δ 3.63
(t, 2H, J = 6.46 Hz) 3.95 (br s, 2H) 4.56 (t, 2H, J = 6.36
Hz) 7.10 (dd, 1H, J = 2.58 Hz, 8.54 Hz) 7.43 (d, 1H, J =
2.58 Hz) 7.54 (d, 1H, J = 8.74 Hz); 13C NMR: δ 28.18,
69.87, 93.59, 113.09, 119.21, 123.54, 124.04, 128.24,
145.63, 149.90, 159.47.
7-Amino-3-(3-bromopropoxy)-4-chloro-1H-iso-
chromen-1-one (6b) (75% yield) Yellow crystals: mp
106–107°C (lit. [24,26] 98–100°C); 1H NMR (DMSO-
d6) δ 2.29 (m, 2H) 3.60 (t, 2H, J = 6.36 Hz) 4.42 (t, 2H, J
= 5.76 Hz) 7.09 (dd, 1H, J = 2.09 Hz, 8.44 Hz) 7.42 (d,
1H, J = 1.99 Hz) 7.51 (d, 1H, J = 8.54 Hz); 13C NMR: δ
29.11, 32.36, 68.71, 93.35, 113.11, 119.17, 123.58,
123.91, 128.42, 145.56, 150.49, 159.74.
2- [2-(7-amino-4-chloro-1-oxo-1H-isochromen-3-
yloxy)ethyl]isothiourea hydrobromide (7a) (40% yield)
Pale yellow solid: mp d 150°C; 1H NMR: (DMSO-d6) δ
3.59 (br s, 2H) 4.47 (br s, 2H) 5.81 (br s, 2H) 7.21 (d, 1H,
J = 8.94 Hz) 7.26 (s, 1H) 7.44 (br d, 1H) 9.11 (br s,
4H);13C NMR: δ 29.73, 68.11, 90.48, 117.18, 121.72,
126.70, 129.48, 135.99, 136.56, 152.18, 158.35, 169.11.
2- [3-(7-Amino-4-chloro-1-oxo-1H-isochromen-3-
yloxy)propyl]isothiourea hydrobromide (7b) A solu-
tion of 6b (0.25 g, 0.75 mmol), thiourea (0.071 g, 0.94
mmol) and tetrahydrofuran (25 mL) was refluxed for
forty-eight hours to give a yellow precipitate. The precipi-
tate was filtered and washed with hot tetrahydrofuran (3BMC Chemical Biology 2006, 6:1 http://www.biomedcentral.com/1472-6769/6/1
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× 25 mL), and recrystallized from methanol/ether to give
0.06 g (20%) of compound 7b as a pale yellow solid: mp
173°C; (lit. [24] 160–162°C); 1H NMR: (DMSO-d6) δ
2.07 (br s, 2H) 3.30 (br s, 2H) 4.32 (br s, 2H) 7.16 (d, 1H,
J = 7.94 Hz) 7.26 (s, 1H) 7.41 (d, 1H, J = 7.95 Hz) 9.05
(br s, 4H);13C NMR: δ 26.73, 28.35, 69.26, 92.87, 110.88,
118.81, 122.84, 123.11, 124.66, 148.23, 149.41, 159.06,
169.37.
N- [3-(2-Bromoethoxy)-4-chloro-1-oxo-1H-iso-
chromen-7-yl]benzamide (8a) To a solution of 6a (0.75
g, 2.4 mmol) in dry tetrahydrofuran (20 mL) was added
benzoyl chloride (0.35 mL, 2.8 mmol) and triethylamine
(0.33 mL, 2.3 mmol). The solution was stirred at room
temperature for fourteen hours after which time the tri-
ethylamine hydrochloride was filtered off and washed
with hot tetrahydrofuran (2 × 10 mL). The filtrate was
evaporated to give a pale yellow solid that was recrystal-
lized from tetrahydrofuran/hexane to afford 0.60 g (75%)
of compound 8a as a pale yellow solid: mp 214–216°C;
1H NMR: (DMSO-d6) δ 3.83 (t, 2H, J = 5.46 Hz) 4.65 (t,
2H, J = 5.46 Hz) 7.56 (m, 3H) 7.71 (d, 1H, J = 8.93 Hz)
7.99 (d, 2H, J = 8.15) 8.29 (dd, 1H, J = 2.39 Hz, 8.74 Hz)
8.68 (d, 1H, J = 2.18 Hz) 10.63 (s, 1H); 13C NMR: δ 30.49,
69.98, 91.08, 117.64, 119.23, 122.38, 127.52, 127.86,
128.20, 131.62, 131.90, 134.12, 137.90, 151.40, 158.35,
165.43. Exact mass calcd for C18H13BrClNO4: 420.9716,
observed (M+H) 421.9788.
N- [3-(3-Bromopropoxy)-4-chloro-1-oxo-1H-iso-
chromen-7-yl]benzamide (8b) (82% yield) Pale yellow
solid: mp 193–194°C; 1H NMR: (DMSO-d6) δ 2.28 (m,
2H) 3.66 (t, 2H, J = 6.56 Hz) 4.44 (t, 2H, J = 5.96 Hz) 7.55
(m, 3H) 7.68 (d, 1H, J = 8.74 Hz) 7.98 (d, 6.56 Hz) 8.25
(dd, 1H, J = 1.99 Hz, 8.74 Hz) 8.66 (d, 1H, J = 1.98 Hz)
10.62 (s, 1H); 13C NMR: δ 30.74, 32.09, 69.13, 91.36,
118.01, 119.74, 122.80, 127.88, 128.43, 128.67, 133.10,
132.46, 134.47, 138.15, 152.20, 158.95, 165.96. Exact
mass calcd for C19H15BrClNO4: 434.9873, observed
(M+H) 435.9959.
2- [2-(7-Benzamido-4-chloro-1-oxo-1H-isochromen-3-
yloxy)ethyl]isothiourea hydrobromide (9a) A solution
of  8a  (0.3 g, 0.71 mmol) and thiourea (0.06 g, 0.78
mmol) in dry tetrahydrofuran (25 mL) was refluxed for
twelve hours. The resulting pale yellow solids were filtered
and washed with hot tetrahydrofuran (3 × 10 mL) to give
0.06 g (17%) of compound 9a as a pale yellow solid: mp
173–175°C. Evaporation of the filtrate afforded 8a (0.2
g). Yield based on recovered starting material is 51%; 1H
NMR: (DMSO-d6) δ 3.68 (br s, 2H) 4.60 (br s, 2H) 7.59
(m, 3H) 7.74 (d, 1H, J = 8.54 Hz) 8.03 (d, 2H, J = 6.75 Hz)
8.32 (d, 1H, J = 8.14 Hz) 8.73 (s, 1H) 9.18 (br s, 4H)
10.69 (s, 1H); 13C NMR: δ 29.85, 68.32, 91.00, 117.72,
119.47, 122.53, 127.60, 128.22, 128.33, 131.79, 132.06,
134.12, 137.96, 151.44, 158.43, 165.63, 169.18.
2- [3-(7-Benzamido-4-chloro-1-oxo-1H-isochromen-3-
yloxy]propyl)isothiourea hydrobromide (9b) (25%
yield) Pale yellow solid: mp 203–204°C;1H NMR:
(DMSO-d6) δ 2.12 (m, 2H) 3.31 (br s, 2H) 4.44 (t, 2H, J
= 5.66 Hz) 7.56 (m, 3H) 7.71 (d, 1H, J = 8.74 Hz) 8.00 (d,
2H, J = 6.95 Hz) 8.28 (d, 1H, J = 8.54 Hz) 8.70 (s, 1H)
9.07 (br s, 4H) 10.65 (s, 1H); 13C NMR: δ 27.21, 28.79,
69.37, 91.38, 118.13, 119.85, 122.92, 128.04, 128.60,
128.77, 132.21, 132.57, 134.61, 138.33, 152.36, 159.05,
166.02, 169.83. Exact mass calcd for C20H18ClN3O4S:
431.0707, observed (M+H) 432.0780.
3-(2-Bromoethoxy)-7-nitro-1H-isochromen-1-one
(10a) A solution of 3a (1.5 g, 4.5 mmol) and trifluoroace-
tic anhydride (0.64 mL, 5.0 mmol) in dichloromethane
(50 mL) was stirred at room temperature for sixteen
hours. The solution was evaporated, washed with water (1
× 25 mL), saturated sodium bicarbonate solution (1 × 25
mL), dried over magnesium sulfate, and evaporated to
afford 1.23 g (87%) of a crude yellow solid. Recrystalliza-
tion from isopropanol gave 0.66 g (47%) of compound
10a as yellow crystals: mp 95–97°C; 1H NMR: δ 3.65 (t,
2H, J = 5.96 Hz) 4.54 (t, 2H, J = 5.86 Hz) 5.77 (s, 1H) 7.42
(d, 1H, J = 8.74 Hz) 8.38 (d, 1H, J = 8.54 Hz) 8.96 (s, 1H);
13C NMR: δ 27.51, 68.87, 81.12, 117.12, 125.70, 126.17,
129.28, 144.97, 145.11, 158.81, 160.02.
3-(3-Bromopropoxy)-7-nitro-1H-isochromen-1-one
(10b) (55% yield) Yellow crystals: mp 117–118°C; 1H
NMR: δ 2.37 (m, 2H) 3.59 (t, 2H, J = 6.26 Hz) 4.38 (t, 2H,
J = 5.86 Hz) 5.72 (s, 1H) 7.43 (d, 1H, J = 8.74 Hz) 8.41
(dd, 1H, J = 2.48 Hz, 8.84 Hz) 9.02 (d, 1H, J = 2.19
Hz);13C NMR: δ 28.80, 31.46, 67.29, 80.02, 117.02,
125.55, 126.07, 129.15, 144.79, 145.21, 158.94, 160.89.
3-(3-Bromopropoxy)-4-trifluoroacetyl-1H-isochromen-
1-one (10c) A solution of 3d (0.60 g, 2.0 mmol) and trif-
luoroacetic anhydride (0.38 mL, 2.7 mmol) in dichlo-
romethane (25 mL) was stirred at room temperature for
fourteen hours. The solution was evaporated and the oil
was chromatographed (chloroform) to afford 0.45 g
(59%) of compound 10c  as white crystals: mp 116–
117°C; 1H NMR: δ 2.38 (m, 2H) 3.54 (t, 2H, J = 6.26 Hz)
4.70 (t, 2H, J = 5.96 Hz) 7.42 (m, 1H) 7.74 (m, 1H) 8.10
(d, 1H, J = 8.34 Hz) 8.22 (d, 1H, J = 7.95 Hz); 13C NMR:
δ 28.24, 31.37, 68.94, 90.90, 115.81, 116.01, 123.40,
126.75, 130.26, 135.87, 136.27, 157.73, 162.08, 179.97.
Anal. Calcd. for C14H10BrF3O4: C, 44.35; H, 2.66. Found:
C, 44.25; H, 2.99.
7-Amino-3-(2-bromoethoxy)-1H-isochromen-1-one
(11) A solution of 10a (1.5 g, 4.7 mmol) in methanol/Publish with BioMed Central    and   every 
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ethyl acetate (1:1, 25 mL) was reduced on a Parr apparatus
with hydrogen and 10% palladium on charcoal. After the
reaction stopped absorbing hydrogen it was filtered
through celite and the celite was washed with methylene
chloride (3 × 50 mL). The filtrate was evaporated to near
dryness keeping the temperature below 40°C. The semi-
solid was recrystallized from methylene chloride/metha-
nol to afford 1.10 g (81%) of compound 11 as yellow
crystals: mp > 280°C; 1H NMR: (DMSO-d6) 3.79 (t, 2H, J
= 5.17 Hz) 4.36 (t, 2H, J = 4.97 Hz) 5.50 (s, 2H) 5.82 (s,
1H) 7.03 (d, 1H, J = 8.54 Hz) 7.19 (m, 2H); 13C NMR: δ
30.30, 68.71, 80.35, 110.20, 117.91, 123.17, 125.84,
128.03, 147.16, 154.71, 160.45.
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